logo
  • 首页
  • 学术期刊
  • 论文检测
  • AIGC检测
  • 热点
  • 更多
    • 数据

Atezolizumab/ipilimumab/pembrolizumabColitis and ulcer: 3 case reports

被引:0
|
作者:
机构:
来源:
Reactions Weekly | 2018年 / 1699卷 / 1期
关键词:
D O I:
10.1007/s40278-018-45309-8
中图分类号:
学科分类号:
摘要:
引用
收藏
页码:40 / 40
相关论文
共 50 条
  • [41] Ipilimumab/nivolumabOesophagitis and pneumonitis: 3 case reports
    Reactions Weekly, 2021, 1866 (1) : 226 - 226
  • [42] Ipilimumab/nivolumabVarious toxicities: 3 case reports
    Reactions Weekly, 2022, 1902 (1) : 255 - 255
  • [43] Ipilimumab/nivolumabVarious toxicities: 3 case reports
    Reactions Weekly, 2021, 1865 (1) : 242 - 242
  • [44] Ipilimumab/nivolumabVarious toxicities: 3 case reports
    Reactions Weekly, 2020, 1811 (1) : 161 - 161
  • [45] Ipilimumab/tremelimumabGraves disease: 3 case reports
    Reactions Weekly, 2015, 1579 (1) : 236 - 236
  • [46] Ipilimumab/pembrolizumabVarious toxicities: 3 case reports
    Reactions Weekly, 2018, 1697 (1) : 214 - 214
  • [47] Ipilimumab/nivolumab/pembrolizumabSarcoidosis: 3 case reports
    Reactions Weekly, 2017, 1678 (1) : 109 - 109
  • [48] Atezolizumab/ipilimumab/nivolumabHepatic immune related adverse event and elevated bilirubin: 2 case reports
    Reactions Weekly, 2025, 2057 (1) : 62 - 62
  • [49] Atezolizumab/pembrolizumabMild myocarditis and dermatitis: 3 case reports
    Reactions Weekly, 2023, 1944 (1) : 126 - 126
  • [50] Atezolizumab/bevacizumabFatigue and variceal bleed: 3 case reports
    Reactions Weekly, 2023, 1968 (1) : 58 - 58
← 12345 →